The Singaporean government has launched two new certification courses for clinical researchers in a bid to “deepen the pool of skilled manpower” available to the country’s rapidly expanding contract research sector.
Singapore's Economic Development Board has been taking strides over
the past year to further its biomedical sciences industry and vie
for global attention amidst the other Asia Pacific players,
particularly in the field of translational...
As Swiss firm Lonza announced last week that it has broken ground
at its second manufacturing site in Singapore, the region looks set
for growth in biologics manufacture with biological products due to
take centre stage in the pharma...
In the company's largest investment of its kind in Asia,
GlaxoSmithKline (GSK) has decided to build a new vaccine
manufacturing plant in Singapore, as several products in its
pipeline approach commercialisation.
Singapore's Ministry of Trade & Industry (MTI) will commit
$7.5bn (€63.1bn) over the next five years to drive R&D growth
in key industry areas such as biomedical science and increase
national R&D spending to 3 per...
Singapore's commitment to pharmaceutical research and development
goes from strength to strength after its government granted S$7.5bn
(€3.9bn) to sustain the innovation-driven growth the country has
experienced as Asia's...
Singapore's pharmaceutical output is likely to be flat this year, a
casualty of increasing pressure from generic drug firms. The
prediction, made by a Singapore official comes after the country
experienced a 40 per cent growth...
Singapore's manufacturing output, which includes pharmaceutical
technology, recorded a 33 per cent growth in 2004, achieving this
target one year ahead of schedule and exceeding projected figures
compiled in 2000.
Singapore-based biologics contract manufacturer, A-Bio Pharma has
won its first contract after entering into a process development
and clinical supply service agreement with GlaxoSmithKline's
vaccine division, GlaxoSmithKline...